02/07/2024

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

02/07/2024

Jul 2, 2024, 11:48 | Blog
Eduardo TB: Deepening treatment with PRRT in NETs
Eduardo TB, Medical Oncologist at University Hospital of Salamanca, shared on X: "Deepening treatment with PRRT…
Jul 2, 2024, 11:44 | Blog
Julie McCrossin: Cancer patients need "open and honest communication about prognosis"
Julie McCrossin, Australian Journalist, Radio broadcaster and Cancer Survivor, shared on LinkedIn:       …
Jul 2, 2024, 11:41 | Insight
Myeloma Paper of the Day, July 2nd, suggested by Robert Orlowski
Robert Orlowski shared on X: "Myeloma Paper of the Day: Leukocyte Ig-like receptor B family…
Jul 2, 2024, 11:31 | Blog
Challenges in non-muscle invasive bladder cancer by Ashish Kamat
Enrique Grande shared on X:          . "Brilliant talk about challenges in…
Jul 2, 2024, 11:15 | Insight
Lucio N. Gordan: Addressing the Unique Needs of our Nation’s Veterans Diagnosed with Cancer
Lucio N. Gordan, President and Managing Physician at Florida Cancer Specialists and Research Institute, shared…
Jul 2, 2024, 11:12 | Blog
Enrique Grande: Fabulous and inspiring view of the short term future of advanced bladder cancer
Enrique Grande shared a post on X:                 …
Jul 2, 2024, 10:56 | Blog
Applications for the next edition of the SIOP Europe Course are now open! 
Ruzanna Papyan shared a post by the European Society for Paediatric Oncology (SIOPE) on LinkedIn,…
Jul 2, 2024, 10:50 | Insight
The path to leptomeningeal metastasis
Jean-Charles Soria shared a post on LinkedIn:  . "Leptomeningeal metastasis occurs in 5-10% of patients…
Jul 2, 2024, 10:42 | Insight
Renee Read: The role of the glioma microenvironment in shaping tumor heterogeneity and progression
Renee Read, Associate Professor at Emory University School of Medicine, shared a post on LinkedIn:…
Jul 2, 2024, 10:32 | Insight
Trastuzumab emtansine (T-DM1) is highly effective in preventing stage 1 HER2-positive breast cancer from recurring - MedEdge MEA
MedEdge MEA shared a post on LinkedIn:  . "A year of treatment with a medicine…
All: 104 Posts: 61 - 70
Special Coverage